Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T2345 unpreserved versus Xalatan in ocular hypertension or glaucoma
2009-011157-41Phase 3Completed
- Sponsor
- Laboratoires Théa
- Start
- Jun 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of latanoprost in ocular hypertension and Glaucoma (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Change in intraocular pressure at 9:00 am from baseline to Day 84. Started Jun 2009; status: completed.
02
Drugs
latanoprost
03
Conditions
ocular hypertensionGlaucoma
Beyond the preview
Go deeper on 2009-011157-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011157-41.